Attention deficit and hyperactivity disorder: Controversies of diagnosis and safety of pharmacological and nonpharmacological treatment

Current Drug Safety

Volumn 2, Issue 1, 2007, Pages 33-42

  Benner Davis, Shannon ^a   Heaton, Pamela C ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

ADHD; Adolescents; Gender differences; Pediatrics; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; IMIPRAMINE; METHYLPHENIDATE; PEMOLINE; PLACEBO; PROTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BLURRED VISION; CHILD BEHAVIOR; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CRYING; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIET THERAPY; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG MISUSE; DRUG POTENTIATION; DRUG SAFETY; DYSKINESIA; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; FAMILY COUNSELING; GASTROINTESTINAL DISEASE; GROWTH INHIBITION; HEADACHE; HEART PALPITATION; HUMAN; HYPERTHERMIA; INCREASED APPETITE; INSOMNIA; INTERMETHOD COMPARISON; IRRITABILITY; LIVER DYSFUNCTION; MASSAGE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDLINE; MILIEU THERAPY; NAUSEA AND VOMITING; NERVOUSNESS; NIGHTMARE; PARENT COUNSELING; PARENTAL BEHAVIOR; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PLAY THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; PULSE RATE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; REWARD; SEIZURE; SEX DIFFERENCE; SIDE EFFECT; SLEEP DISORDER; SUBSTANCE ABUSE; SUDDEN DEATH; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TIC; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; YOGA;

ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR THERAPY; BIOFEEDBACK (PSYCHOLOGY); CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COMPLEMENTARY THERAPIES; HUMANS; SAFETY; YOGA;

EID: 34248175924     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607779315444     Document Type: Review

References (73)

1. Burd L, Klug MG, Coumbe MJ, Kerbeshian J. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol 2003; 18: 555-61.
2. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch Pediatr Adolesc Med 2002; 156: 504-11.
3. Guevara J, Lozano P, Wickizer T, Mell L, Gephart H. Utilization and cost of health care services for children with attention-deficit/ hyperactivity disorder. Pediatrics 2001; 108: 71-8.
4. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005; 3: 5.
5. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033-44.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th. ed. Washington DC: American Psychiatric Association; 2000.
7. National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficity hyperactivity disorder (ADHD) in children and adolescents. Technology Appraisal 98. Last Accessed August 1, 2006. www.nice.org.uk.
8. National Institute for Health and Clinical Excellence. Parent-training/ education programmes in the management of children with conduct disorders. NICE Technology Appraisal Guidance 102. Last Accessed August 1, 2006. www.nice.org.uk.
9. Taylor E, Sandber S, Thorley G, Gilles S. The epidemiology of childhood hyperactivity. ed. Oxford, England: Oxford University Press; 1991.
10. Gadow KD, Nolan EE, Litcher L, et al. Comparison of attention-deficit/hyperactivity disorder symptom subtypes in Ukrainian schoolchildren. J Am Acad Child Adolesc Psychiatry 2000; 39: 1520-7.
11. The American Academy of Pediatrics Online. www.aap.org. Last accessed on June 6.
12. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 1997; 36: 1036-45.
13. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002; 159: 36-42.
14. Abikoff HB, Jensen PS, Arnold LL, et al. Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. J Abnorm Child Psychol. 2002; 30: 349-59.
15. Biederman J, Kwon A, Aleardi M, et al. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry 2005; 162: 1083-9.
16. Facts and Comparisons Online. www.factsandcomparisons.com Last accessed on May 30, 2006.
17. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: E105.
18. Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999; 104: 1300-11.
19. Denisco S, Tiago C, Kravitz C. Evaluation and treatment of pediatric ADHD. Nurse Pract 2005; 30: 14-17, 19-23; quiz 24-5.
20. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115: e749-57.
21. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41: 26S-49S.
22. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100: 662-6.
23. Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab 2003; 16: 711-8.
24. Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 2003; 39: 180-5.
25. Sund AM, Zeiner P. Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? Nord J Psychiatry 2002; 56: 53-7.
26. Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 2004; 14: 185-94.
27. Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1999; 38: 944-51.
28. Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1994; 148: 859-61.
29. Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry 2001; 42: 228-33.
30. Mannuzza S, Klein RG, Moulton JL 3rd. Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. J Child Adolesc Psychopharmacol 2003; 13: 273-82.
31. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63(Suppl 12): 50-5.
32. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776-84.
33. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729-40.
34. Hazell PL, McDowell MJ, Walton JM. Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of NSW. Med J Aust 1996; 165: 477-80.
35. Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2003; 160: 1071-7.
36. Cantwell DP, Swanson J, Connor DF. Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry 1997; 36: 539-44.
37. Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 1999; 38: 614-9; discussion 619-22.
38. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42: 886-94.
39. Kappagoda C, Schell DN, Hanson RM, Hutchins P. Clonidine overdose in childhood: implications of increased prescribing. J Paediatr Child Health 1998; 34: 508-12.
40. Safer DJ. Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry 2000; 12: 55-62.
41. Rafalovich A. Exploring clinician uncertainty in the diagnosis and treatment of attention deficit hyperactivity disorder. Sociol Health Illn 2005; 27: 305-23.
42. Kramer P. Listening to prozac: a psychiatrist explores antidepressant drugs and the remaking of the self. ed. New York: Penguin Press; 1993.
43. Bussing R, Zima BT, Gary FA, Garvan CW. Barriers to detection, help-seeking, and service use for children with ADHD symptoms. J Behav Health Serv Res 2003; 30: 176-89.
44. Stevens J., Harman JS., Kelleher KJ. Ethnic and regional differences in primary care visits for attention-deficit hyperactivity disorder. J of Develop Behav Ped 2004; 25: 318-25.
45. Stevens J, Harman JS, Kelleher KJ. Race/ethnicity and insurance status as factors associated with ADHD treatment patterns. J Child Adolesc Psychopharmacol 2005; 15: 88-96.
46. Lin SJ, Crawford SY, Lurvey PL. Trend and area variation in amphetamine prescription usage among children and adolescents in Michigan. Soc Sci Med 2005; 60: 617-26.
47. Rappley MD, Gardiner JC, Jetton JR, Houang RT. The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 1995; 149: 675-9.
48. Barkley RA. Psychosocial treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002; 63(Suppl 12): 36-43.
49. Miranda A, Presentacion MJ, Soriano M. Effectiveness of a schoolbased multicomponent program for the treatment of children with ADHD. J Learn Disabil 2002; 35: 546-62.
50. Fehlings DL, Roberts W, Humphries T, Dawe G. Attention deficit hyperactivity disorder: does cognitive behavioral therapy improve home behavior? J Dev Behav Pediatr 1991; 12: 223-8.
51. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56: 1073-86.
52. Pelham WE, Burrows-Maclean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 2005; 13: 111-26.
53. Salamone JD, Correa M, Mingote SM, Weber SM. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol 2005; 5: 34-41.
54. Pierce RC, Crawford CA, Nonneman AJ, Mattingly BA, Bardo MT. Effect of forebrain dopamine depletion on novelty-induced place preference behavior in rats. Pharmacol Biochem Behav 1990; 36: 321-5.
55. Feenstra MG, Botterblom MH, van Uum JF. Novelty-induced increase in dopamine release in the rat prefrontal cortex in vivo: inhibition by diazepam. Neurosci Lett 1995; 189: 81-4.
56. Schultz W. Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. Curr Opin Neurobiol 2004; 14: 139-47.
57. Flaherty CF. Incentive relativity. ed. Cambridge, UK: Cambridge University Press; 1996.
58. Rojas NL, Chan E. Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder. Ment Retard Dev Disabil Res Rev 2005; 11: 116-30.
59. Mann CA, Lubar JF, Zimmerman AW, Miller CA, Muenchen RA. Quantitative analysis of EEG in boys with attention-deficit-hyperactivity disorder: controlled study with clinical implications. Pediatr Neurol 1992; 8: 30-6.
60. Marcason W. Can dietary intervention play a part in the treatment of attention deficit and hyperactivity disorder? J Am Diet Assoc 2005; 105: 1161-2.
61. Carlson CL, Tamm L, Gaub M. Gender differences in children with ADHD, ODD, and co-occurring ADHD/ODD identified in a school population. J Am Acad Child Adolesc Psychiatry 1997; 36: 1706-14
62. Rucklidge JJ, Tannock R. Psychiatric, psychosocial, and cognitive functioning of female adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40: 530-40.
63. Yang P, Jong YJ, Chung LC, Chen CS. Gender differences in a clinic-referred sample of Taiwanese attention-deficit/hyperactivity disorder children. Psychiatry Clin Neurosci 2004; 58: 619-23.
64. Havey JM, Olson JM, McCormick C, Cates GL. Teachers' perceptions of the incidence and management of attention-deficit hyperactivity disorder. Appl. Neuropsychol 2005; 12: 120-7.
65. Graetz BW, Sawyer MG, Baghurst P. Gender differences among children with DSM-IV ADHD in Australia. J Am Acad Child Adolesc Psychiatry 2005; 44: 159-68.
66. Seidman LJ, Biederman J, Monuteaux MC, Valera E, Doyle AE, Faraone SV. Impact of gender and age on executive functioning: do girls and boys with and without attention deficit hyperactivity disorder differ neuropsychologically in preteen and teenage years? Dev Neuropsychol 2005; 27: 79-105.
67. Levy F, Hay DA, Bennett KS, McStephen M. Gender differences in ADHD subtype comorbidity. J Am Acad Child Adolesc Psychiatry 2005; 44: 368-76.
68. Pelham WE Jr, Carlson C, Sams SE, Vallano G, Dixon MJ, Hoza B. Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom. J Consult Clin Psychol 1993; 61: 506-15.
69. Ajibola O, Clement PW. Differential effects of methylphenidate and self-reinforcement on attention-deficit hyperactivity disorder. Behav Modif 1995; 19: 211-33.
70. Pelham WE, Gnagy EM, Greiner AR, et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol 2000; 28: 507-25.
71. Sonuga-Barke EJ, Daley D, Thompson M, Laver-Bradbury C, Weeks A. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry 2001; 40: 402-8.
72. Dopfner M, Breuer D, Schurmann S, Metternich TW, Rademacher C, Lehmkuhl G. Effectiveness of an adaptive multimodal treatment in children with Attention-Deficit Hyperactivity Disorder-global outcome. Eur Child Adolesc Psychiatry 2004; 13(Suppl 1): I117-29.
73. Arnold LE, Chuang S, Davies M, et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. J Abnorm Child Psychol 2004; 32: 39-51.